Home/Filings/4/0002034679-25-000006
4//SEC Filing

Raben David 4

Accession 0002034679-25-000006

CIK 0002023658other

Filed

Nov 24, 7:00 PM ET

Accepted

Nov 25, 6:39 PM ET

Size

18.9 KB

Accession

0002034679-25-000006

Insider Transaction Report

Form 4
Period: 2025-11-24
Raben David
Chief Medical Officer
Transactions
  • Sale

    Common Stock

    2025-11-24$18.45/sh5,500$101,47535,497 total
  • Exercise/Conversion

    Common Stock

    2025-11-25$3.79/sh+4,594$17,41040,091 total
  • Sale

    Common Stock

    2025-11-25$18.84/sh4,594$86,56235,497 total
  • Exercise/Conversion

    Common Stock

    2025-11-25$3.79/sh+906$3,43436,403 total
  • Sale

    Common Stock

    2025-11-25$18.84/sh906$17,07135,497 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-11-245,500123,370 total
    Exercise: $3.79Exp: 2033-08-08Common Stock (5,500 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-11-254,594118,776 total
    Exercise: $3.79Exp: 2033-08-08Common Stock (4,594 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-11-2590669,413 total
    Exercise: $3.79Exp: 2023-08-08Common Stock (906 underlying)
  • Exercise/Conversion

    Common Stock

    2025-11-24$3.79/sh+5,500$20,84440,997 total
Footnotes (4)
  • [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
  • [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.68 to $19.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
  • [F3]25% of the shares underlying this option vested on July 24, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
  • [F4]The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

Issuer

Bicara Therapeutics Inc.

CIK 0002023658

Entity typeother

Related Parties

1
  • filerCIK 0002034679

Filing Metadata

Form type
4
Filed
Nov 24, 7:00 PM ET
Accepted
Nov 25, 6:39 PM ET
Size
18.9 KB